SPRO vs. CNTB, TPST, HOOK, MRNS, YS, CRVS, ONCY, IFRX, ALRN, and VTVT
Should you be buying Spero Therapeutics stock or one of its competitors? The main competitors of Spero Therapeutics include Connect Biopharma (CNTB), Tempest Therapeutics (TPST), Hookipa Pharma (HOOK), Marinus Pharmaceuticals (MRNS), YS Biopharma (YS), Corvus Pharmaceuticals (CRVS), Oncolytics Biotech (ONCY), InflaRx (IFRX), Aileron Therapeutics (ALRN), and vTv Therapeutics (VTVT). These companies are all part of the "pharmaceutical preparations" industry.
Connect Biopharma (NASDAQ:CNTB) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations, community ranking and media sentiment.
Spero Therapeutics has a net margin of 21.98% compared to Spero Therapeutics' net margin of 0.00%. Connect Biopharma's return on equity of 38.54% beat Spero Therapeutics' return on equity.
In the previous week, Connect Biopharma had 1 more articles in the media than Spero Therapeutics. MarketBeat recorded 3 mentions for Connect Biopharma and 2 mentions for Spero Therapeutics. Connect Biopharma's average media sentiment score of 1.43 beat Spero Therapeutics' score of 0.58 indicating that Spero Therapeutics is being referred to more favorably in the news media.
Connect Biopharma has a beta of -0.62, suggesting that its share price is 162% less volatile than the S&P 500. Comparatively, Spero Therapeutics has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500.
Spero Therapeutics received 184 more outperform votes than Connect Biopharma when rated by MarketBeat users. However, 69.57% of users gave Connect Biopharma an outperform vote while only 69.20% of users gave Spero Therapeutics an outperform vote.
Connect Biopharma currently has a consensus target price of $6.50, suggesting a potential upside of 364.29%. Spero Therapeutics has a consensus target price of $7.00, suggesting a potential upside of 381.10%. Given Connect Biopharma's higher probable upside, analysts plainly believe Spero Therapeutics is more favorable than Connect Biopharma.
58.7% of Connect Biopharma shares are owned by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are owned by institutional investors. 22.6% of Connect Biopharma shares are owned by company insiders. Comparatively, 4.5% of Spero Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Spero Therapeutics has higher revenue and earnings than Connect Biopharma.
Summary
Spero Therapeutics beats Connect Biopharma on 9 of the 13 factors compared between the two stocks.
Get Spero Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SPRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Spero Therapeutics Competitors List
Related Companies and Tools
